Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857. ...
The “Phase 2 randomized, double-blind, placebo-controlled crossover trial to evaluate the safety, tolerability, and efficacy of subcutaneous injections of elamipretide (MTP-131) in subjects with genetically confirmed Barth syndrome followed by an open-label treatment extension (SPIBA 201)” (Clinic...
(NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets ...
Background Sorafenib monotherapy showed activity in a randomized discontinuation phase II trial of patients with advanced NSCLC who failed 2鈥 3 chemotherapy regimens (ECOG 2501). The Phase III MISSION trial assessed whether 3rd- or 4th-l... L. Paz-Ares,V. Hirsh,L. Zhang,... - 《Annals ...
of a randomized phase III trial of the TTD group comparing capecitabine and oxaliplatin (XELOX) vs oxaliplatin and 5-fluorouracil in continuous infusion (... J Sastre,B Massuti,JM Tabernero,... - Satellite Symposium on New Horizons for Gastric Cancer Held in 被引量: 90发表: 2006年 Phase...
common drug-related adverse events (AEs) were typical for this class of agent and consisted predominantly of skin reactions, headache, nausea/vomiting, and fatigue (mostly grade 1 or 2). Importantly, no hypersensitivity or infusion reactions associated with necitumumab were reported in this trial....
The combination of Evo with bevacizumab was well overall well tolerated. One grade 4 drug associated adverse event (AE) of small bowel perforation felt to be likely related to bevacizumab occurred. Eleven grade 3 AEs occurred during the course of the study, including 5 of mucositis, 2 of pain...
Methods ACHIEVE-2 was an open-label, multicenter trial randomizing pts with high-risk stage II CC (T4, inadequate nodal harvest, poorly differentiated, obstruction, perforation or vascular invasion) to receive 3 months (m) or 6m of mFOLFOX6/CAPOX after curative surgery. Choice of regimen was...
This randomized, non-comparative phase II trial evaluated two weekly docetaxel-based regimens to determine which is the most promising in terms of efficacy and safety as a front-line therapy in AGC. Methods Chemotherapy-nave patients with measurable unresectable and/or metastatic gastric adenocarcinoma...
In this multicenter randomized phase III trial, we compared the efficacy and toxicity of 2 active regimens. Previously untreated pts with CUP (adenocarcinoma, poorly differentiated adenocarcinoma, poorly differentiated carcinoma, poorly differentiated squamous carcinoma) were eligible. Pts with specific ...